It is now clear that in some well-defined cases (e.g. myeloma) mis-expressed syndecan can be a driver to disease progression [11], while in others, syndecans are strong prognostic indicators (e.g. breast cancer [12,13]). The gene discussed is SDC1; the disease is plasma cell myeloma.